Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: | Neurology | Family Medicine
Search Medical Condition
Restless Leg Syndrome Clinical Trials
A listing of Restless Leg Syndrome medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Found (17) clinical trials
Blinded, Randomized Study of Gabapentin (Neurontin®) and Gabapentin Enacarbil (Horizant™) in Restless Leg Syndrome
The study will compare the safety, effectiveness and tolerability of gabapentin (Neurontin) versus gabapentin enacarbil (Horizant) as treatment restless leg syndrome.
Does Restless Legs Syndrome have you going in circles?
If you're experiencing symptoms of Restless Legs Syndrome (RLS), learn more about this medical research study of an investigational RLS drug. Local doctors are currently conducting the CONCORD medical research study of a Restless Legs Syndrome (RLS) study drug. They want to evaluate an approved dose strength with two investigational ...
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose, Parallel-Group Study to Compare the Efficacy, Tolerability, and Safety of 3 Doses of Gabapentin Enacarbil (GSK1838262) With Placebo in the Treatment of Subjects With Moderate-to-Severe Primary Restless Legs Syndrome (RLS)
Patient Inclusion Criteria: Ages 18+ RLS diagnosis 15 nights or more in past month with RLS symptoms Must stop all RLS medications 2 weeks prior No Horizant usage in past Men or women 18 years of age or older History of RLS symptoms for at least 15 nights/month Documented RLS ...
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Patient Inclusion Criteria: Ages 18-60 SPMS diagnosis Must be able to walk Diagnosed with MS as defined by the modified McDonald criteria SPMS defined as relapsing-remitting disease with recent progression in MS-related neurological deficits EDSS score 3.0 - 6.0, inclusively Presence of myelin reactive T-cells Patient Exclusion Criteria: Diagnosed with ...
Restless Legs Syndrome patients with iron-deficiency anemia Clinical Research Study
Do you have Restless Legs Syndrome with iron-deficiency anemia?
Randomized Placebo-controlled Trial of Ferric Carboxymaltose in RLS Patients With Iron-deficiency Anemia
This will be a Phase II, randomized, placebo-controlled study. All subjects who meet the inclusion criteria, with no exclusion criteria, will qualify to enter the Screening Phase. The study will enroll 70 eligible subjects to receive blinded study drug in Treatment Phase I. All eligible subjects will be randomized in ...
Executive Dysfunction in Restless Legs Syndrome: Clinical Correlates and Outcome After Therapeutic Management
Restless leg syndrome (RLS) is a common neurological disorder whose diagnosis is only clinical. The efficacy of dopaminergic agents in improvement of sensorimotor symptoms advance the hypothesis that altered dopaminergic transmission is at the origin of this condition. RLS usually leads to a sleep fragmentation, which induces sometimes severe insomnia ...
Cholecalciferol Supplementation in Restless Leg Syndrome in Patients With Chronic Kidney Disease
Restless leg syndrome (RLS) is sleep disorder characterized by an unpleasant feeling in the lower limbs, which can be accompanied by paresthesias, and need for urgent movement of the legs. Its diagnosis is clinical, based on an International Committee of the Study of RLS (International Restless Legs Syndrome Study) questionnaire. ...
Sleep Deficiency and Stroke Outcome
Background Experimental and clinical data suggest a detrimental effect of sleep deficiency/sleep fragmentation on stroke outcome. In rodents, sleep fragmentation and sleep deprivation induced in the acute phase of stroke enhance the extension of the lesion and impair functional recovery - inversely, sleep-promoting drugs have a positive effect on functional ...
A Pharmacokinetic and Safety Evaluation of HORIZANT (Gabapentin Enacarbil) in Adolescents With Moderate-to-Severe Primary RLS
The primary objective is to assess the pharmacokinetics (PK) of gabapentin following the single-dose administration of HORIZANT (Gabapentin Enacarbil) in adolescents (13 to 17 years of age) diagnosed with moderate-to-severe Primary Restless Legs Syndrome (RLS).
